Compare NAII & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAII | DYAI |
|---|---|---|
| Founded | 1980 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 17.0M |
| IPO Year | 1995 | 2026 |
| Metric | NAII | DYAI |
|---|---|---|
| Price | $1.17 | $0.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.3K | ★ 150.1K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $132,437,000.00 | $3,090,345.00 |
| Revenue This Year | N/A | $113.16 |
| Revenue Next Year | N/A | $94.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.60 | N/A |
| 52 Week Low | $1.11 | $0.34 |
| 52 Week High | $4.96 | $1.60 |
| Indicator | NAII | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 19.21 | 33.80 |
| Support Level | N/A | $0.34 |
| Resistance Level | $2.83 | $0.50 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 7.26 | 10.10 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.